Overview
Mesa Laboratories fiscal Q2 revenue grows 5%, operating income rises 34.7%
Net income for fiscal Q2 decreases 27.8% compared to prior year
Biopharmaceutical Development and Calibration Solutions show strong growth despite CG challenges
Outlook
Mesa expects sequential revenue growth in 3Q26
Company plans to reinvest $0.9M savings into SDC for long-term growth
Mesa anticipates continued revenue declines in China for FY26
Result Drivers
BPD GROWTH - Biopharmaceutical Development division saw strong revenue growth driven by higher sales of Peptides instruments and delayed bookings from 1Q26
COST REDUCTIONS - Mesa reduced annualized costs by $3.2M to align with global tariffs and currency headwinds, with $2.1M reductions in CG
CG CHALLENGES - Clinical Genomics division faced a 58% revenue decline in China due to macroeconomic and regulatory headwinds
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | $0.45 | ||
Q2 Net Income | $2.48 mln | ||
Q2 Basic EPS | $0.45 | ||
Q2 Gross Profit | $37.33 mln | ||
Q2 Operating Expenses | $32.61 mln | ||
Q2 Operating Income | $4.72 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Mesa Laboratories Inc is $88.50, about 16.2% above its November 5 closing price of $74.20
The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago
Press Release: ID:nGNXfPL84
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments